Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer
Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity and overall survival time of gefitinib treatmen...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2005-01, Vol.25 (1B), p.435-441 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 441 |
|---|---|
| container_issue | 1B |
| container_start_page | 435 |
| container_title | Anticancer research |
| container_volume | 25 |
| creator | KONISHI, Jun YAMAZAKI, Koichi HATTORI, Takeshi ASAHINA, Hajime IMURA, Mikado KIKUCHI, Eiki KIKUCHI, Junko SHINAGAWA, Naofumi YOKOUCHI, Hiroshi MUNAKATA, Mitsuru DOSAKA-AKITA, Hirotoshi NISHIMURA, Masaharu KINOSHITA, Ichiro ISOBE, Hiroshi OGURA, Shigeaki SEKINE, Satoko ISHIDA, Takashi TAKASHIMA, Riou NAKADATE, Megumi NISHIKAWA, Shyu |
| description | Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which
had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity
and overall survival time of gefitinib treatment in patients with NSCLC. Patients and Methods: One hundred and twenty-two
patients with NSCLC, who received gefitinib between 2002 and 2004 in our institutes, were evaluated retrospectively. Results:
The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and
smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included
good performance status (PS), female, adenocarcinoma and never smoked status, while never smoked status and good PS were independent
prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib.
Conclusion: Gefitinib showed favorable antitumor activity in females, never smokers and adenocarcinoma. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_15816608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15816608</sourcerecordid><originalsourceid>FETCH-LOGICAL-h313t-44c8407b873e90f63894aca13738f0c6afd06538c6b4604f2cc3f044ccd3fa5b3</originalsourceid><addsrcrecordid>eNpFz1FLwzAQB_AgipvTryB58bFw6SVp-jiLbsJQkflc0jRZI106mg7dt7fqZC93L7_7c_8zMmVZzpJMIJyTKaQCkgxATMhVjB8AUuYKL8mECcWkBDUlr_Og20P0kXaODo2lbzbuuhAt1aGm6-7LGz8c6NDRhXV-8MFXP_K5C0nc6ralhR3Hah82tNDB2P6aXDjdRntz3DPy_viwLpbJ6mXxVMxXSYMMh4RzozhklcrQ5uAkqpxroxlmqBwYqV0NUqAysuISuEuNQQfjlanRaVHhjNz-5e721dbW5a73W90fyv9qI7g7Ah2Nbl0_vufjyUkpU8zSk2v8pvn0vS1_i42xWOo-FSW7LzkK_AYtqWQ7</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KONISHI, Jun ; YAMAZAKI, Koichi ; HATTORI, Takeshi ; ASAHINA, Hajime ; IMURA, Mikado ; KIKUCHI, Eiki ; KIKUCHI, Junko ; SHINAGAWA, Naofumi ; YOKOUCHI, Hiroshi ; MUNAKATA, Mitsuru ; DOSAKA-AKITA, Hirotoshi ; NISHIMURA, Masaharu ; KINOSHITA, Ichiro ; ISOBE, Hiroshi ; OGURA, Shigeaki ; SEKINE, Satoko ; ISHIDA, Takashi ; TAKASHIMA, Riou ; NAKADATE, Megumi ; NISHIKAWA, Shyu</creator><creatorcontrib>KONISHI, Jun ; YAMAZAKI, Koichi ; HATTORI, Takeshi ; ASAHINA, Hajime ; IMURA, Mikado ; KIKUCHI, Eiki ; KIKUCHI, Junko ; SHINAGAWA, Naofumi ; YOKOUCHI, Hiroshi ; MUNAKATA, Mitsuru ; DOSAKA-AKITA, Hirotoshi ; NISHIMURA, Masaharu ; KINOSHITA, Ichiro ; ISOBE, Hiroshi ; OGURA, Shigeaki ; SEKINE, Satoko ; ISHIDA, Takashi ; TAKASHIMA, Riou ; NAKADATE, Megumi ; NISHIKAWA, Shyu</creatorcontrib><description>Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which
had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity
and overall survival time of gefitinib treatment in patients with NSCLC. Patients and Methods: One hundred and twenty-two
patients with NSCLC, who received gefitinib between 2002 and 2004 in our institutes, were evaluated retrospectively. Results:
The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and
smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included
good performance status (PS), female, adenocarcinoma and never smoked status, while never smoked status and good PS were independent
prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib.
Conclusion: Gefitinib showed favorable antitumor activity in females, never smokers and adenocarcinoma.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 15816608</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Adenocarcinoma - metabolism ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Female ; Humans ; Lung Neoplasms - drug therapy ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Pneumology ; Proportional Hazards Models ; Quinazolines - therapeutic use ; Retrospective Studies ; Sex Factors ; Smoking ; Time Factors ; Treatment Outcome ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Anticancer research, 2005-01, Vol.25 (1B), p.435-441</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16662372$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15816608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KONISHI, Jun</creatorcontrib><creatorcontrib>YAMAZAKI, Koichi</creatorcontrib><creatorcontrib>HATTORI, Takeshi</creatorcontrib><creatorcontrib>ASAHINA, Hajime</creatorcontrib><creatorcontrib>IMURA, Mikado</creatorcontrib><creatorcontrib>KIKUCHI, Eiki</creatorcontrib><creatorcontrib>KIKUCHI, Junko</creatorcontrib><creatorcontrib>SHINAGAWA, Naofumi</creatorcontrib><creatorcontrib>YOKOUCHI, Hiroshi</creatorcontrib><creatorcontrib>MUNAKATA, Mitsuru</creatorcontrib><creatorcontrib>DOSAKA-AKITA, Hirotoshi</creatorcontrib><creatorcontrib>NISHIMURA, Masaharu</creatorcontrib><creatorcontrib>KINOSHITA, Ichiro</creatorcontrib><creatorcontrib>ISOBE, Hiroshi</creatorcontrib><creatorcontrib>OGURA, Shigeaki</creatorcontrib><creatorcontrib>SEKINE, Satoko</creatorcontrib><creatorcontrib>ISHIDA, Takashi</creatorcontrib><creatorcontrib>TAKASHIMA, Riou</creatorcontrib><creatorcontrib>NAKADATE, Megumi</creatorcontrib><creatorcontrib>NISHIKAWA, Shyu</creatorcontrib><title>Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which
had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity
and overall survival time of gefitinib treatment in patients with NSCLC. Patients and Methods: One hundred and twenty-two
patients with NSCLC, who received gefitinib between 2002 and 2004 in our institutes, were evaluated retrospectively. Results:
The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and
smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included
good performance status (PS), female, adenocarcinoma and never smoked status, while never smoked status and good PS were independent
prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib.
Conclusion: Gefitinib showed favorable antitumor activity in females, never smokers and adenocarcinoma.</description><subject>Adenocarcinoma - metabolism</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pneumology</subject><subject>Proportional Hazards Models</subject><subject>Quinazolines - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Sex Factors</subject><subject>Smoking</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFz1FLwzAQB_AgipvTryB58bFw6SVp-jiLbsJQkflc0jRZI106mg7dt7fqZC93L7_7c_8zMmVZzpJMIJyTKaQCkgxATMhVjB8AUuYKL8mECcWkBDUlr_Og20P0kXaODo2lbzbuuhAt1aGm6-7LGz8c6NDRhXV-8MFXP_K5C0nc6ralhR3Hah82tNDB2P6aXDjdRntz3DPy_viwLpbJ6mXxVMxXSYMMh4RzozhklcrQ5uAkqpxroxlmqBwYqV0NUqAysuISuEuNQQfjlanRaVHhjNz-5e721dbW5a73W90fyv9qI7g7Ah2Nbl0_vufjyUkpU8zSk2v8pvn0vS1_i42xWOo-FSW7LzkK_AYtqWQ7</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>KONISHI, Jun</creator><creator>YAMAZAKI, Koichi</creator><creator>HATTORI, Takeshi</creator><creator>ASAHINA, Hajime</creator><creator>IMURA, Mikado</creator><creator>KIKUCHI, Eiki</creator><creator>KIKUCHI, Junko</creator><creator>SHINAGAWA, Naofumi</creator><creator>YOKOUCHI, Hiroshi</creator><creator>MUNAKATA, Mitsuru</creator><creator>DOSAKA-AKITA, Hirotoshi</creator><creator>NISHIMURA, Masaharu</creator><creator>KINOSHITA, Ichiro</creator><creator>ISOBE, Hiroshi</creator><creator>OGURA, Shigeaki</creator><creator>SEKINE, Satoko</creator><creator>ISHIDA, Takashi</creator><creator>TAKASHIMA, Riou</creator><creator>NAKADATE, Megumi</creator><creator>NISHIKAWA, Shyu</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20050101</creationdate><title>Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer</title><author>KONISHI, Jun ; YAMAZAKI, Koichi ; HATTORI, Takeshi ; ASAHINA, Hajime ; IMURA, Mikado ; KIKUCHI, Eiki ; KIKUCHI, Junko ; SHINAGAWA, Naofumi ; YOKOUCHI, Hiroshi ; MUNAKATA, Mitsuru ; DOSAKA-AKITA, Hirotoshi ; NISHIMURA, Masaharu ; KINOSHITA, Ichiro ; ISOBE, Hiroshi ; OGURA, Shigeaki ; SEKINE, Satoko ; ISHIDA, Takashi ; TAKASHIMA, Riou ; NAKADATE, Megumi ; NISHIKAWA, Shyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h313t-44c8407b873e90f63894aca13738f0c6afd06538c6b4604f2cc3f044ccd3fa5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adenocarcinoma - metabolism</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pneumology</topic><topic>Proportional Hazards Models</topic><topic>Quinazolines - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Sex Factors</topic><topic>Smoking</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KONISHI, Jun</creatorcontrib><creatorcontrib>YAMAZAKI, Koichi</creatorcontrib><creatorcontrib>HATTORI, Takeshi</creatorcontrib><creatorcontrib>ASAHINA, Hajime</creatorcontrib><creatorcontrib>IMURA, Mikado</creatorcontrib><creatorcontrib>KIKUCHI, Eiki</creatorcontrib><creatorcontrib>KIKUCHI, Junko</creatorcontrib><creatorcontrib>SHINAGAWA, Naofumi</creatorcontrib><creatorcontrib>YOKOUCHI, Hiroshi</creatorcontrib><creatorcontrib>MUNAKATA, Mitsuru</creatorcontrib><creatorcontrib>DOSAKA-AKITA, Hirotoshi</creatorcontrib><creatorcontrib>NISHIMURA, Masaharu</creatorcontrib><creatorcontrib>KINOSHITA, Ichiro</creatorcontrib><creatorcontrib>ISOBE, Hiroshi</creatorcontrib><creatorcontrib>OGURA, Shigeaki</creatorcontrib><creatorcontrib>SEKINE, Satoko</creatorcontrib><creatorcontrib>ISHIDA, Takashi</creatorcontrib><creatorcontrib>TAKASHIMA, Riou</creatorcontrib><creatorcontrib>NAKADATE, Megumi</creatorcontrib><creatorcontrib>NISHIKAWA, Shyu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KONISHI, Jun</au><au>YAMAZAKI, Koichi</au><au>HATTORI, Takeshi</au><au>ASAHINA, Hajime</au><au>IMURA, Mikado</au><au>KIKUCHI, Eiki</au><au>KIKUCHI, Junko</au><au>SHINAGAWA, Naofumi</au><au>YOKOUCHI, Hiroshi</au><au>MUNAKATA, Mitsuru</au><au>DOSAKA-AKITA, Hirotoshi</au><au>NISHIMURA, Masaharu</au><au>KINOSHITA, Ichiro</au><au>ISOBE, Hiroshi</au><au>OGURA, Shigeaki</au><au>SEKINE, Satoko</au><au>ISHIDA, Takashi</au><au>TAKASHIMA, Riou</au><au>NAKADATE, Megumi</au><au>NISHIKAWA, Shyu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>25</volume><issue>1B</issue><spage>435</spage><epage>441</epage><pages>435-441</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which
had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity
and overall survival time of gefitinib treatment in patients with NSCLC. Patients and Methods: One hundred and twenty-two
patients with NSCLC, who received gefitinib between 2002 and 2004 in our institutes, were evaluated retrospectively. Results:
The objective response rate was 24.6%. The variables identified as significant in univariate analysis included gender and
smoking habit. The median overall survival time was 14.4 months. Significant variables associated with improved survival included
good performance status (PS), female, adenocarcinoma and never smoked status, while never smoked status and good PS were independent
prognostic factors in multivariate analysis. Four patients (3.3%) developed interstitial pneumonitis associated with gefitinib.
Conclusion: Gefitinib showed favorable antitumor activity in females, never smokers and adenocarcinoma.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>15816608</pmid><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2005-01, Vol.25 (1B), p.435-441 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_pubmed_primary_15816608 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adenocarcinoma - metabolism Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Female Humans Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Multivariate Analysis Pneumology Proportional Hazards Models Quinazolines - therapeutic use Retrospective Studies Sex Factors Smoking Time Factors Treatment Outcome Tumors Tumors of the respiratory system and mediastinum |
| title | Analysis of the Response and Toxicity to Gefitinib of Non-small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A14%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20the%20Response%20and%20Toxicity%20to%20Gefitinib%20of%20Non-small%20Cell%20Lung%20Cancer&rft.jtitle=Anticancer%20research&rft.au=KONISHI,%20Jun&rft.date=2005-01-01&rft.volume=25&rft.issue=1B&rft.spage=435&rft.epage=441&rft.pages=435-441&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E15816608%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15816608&rfr_iscdi=true |